BIOATLA, INC. Retained Earnings
BIOATLA, INC. (BCAB) had Retained Earnings of -$551.54 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$551.54M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$551.99M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$545.65M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$535.86M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$551.54M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$551.99M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$545.65M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$535.86M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$520.08M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$501.37M 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$486.04M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$471.15M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$460.57M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$439.50M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$416.26M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$389.34M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$356.01M 10-Q · filed 2023-08-01 |
| 2023-03-31 | -$320.26M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$292.80M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$265.26M 10-Q · filed 2022-11-04 |
| 2022-06-30 | -$239.48M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$210.57M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$186.32M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$162.93M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$140.00M 10-Q · filed 2021-08-13 |
| 2021-03-31 | -$109.62M 10-Q · filed 2021-05-12 |
| 2020-12-31 | -$90.92M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |